Humana Just Made Medicare Advantage the Live Tape — A 20%-to-95% 4-Star Flip While UNH and ELV Slide

Star Ratings matter because they unlock Quality Bonus Payments (5% of benchmark for 4+ stars) and a higher rebate share (65–70% vs 50% for plans below 3.5 stars). Under that formula, moving from a sub-4-star base to a 4-star-plus base for two-thirds of an MA book turns incremental capitation dollars into incremental earnings. HUM just moved roughly six and a half million of its seven million MA members into the bonus-paying bucket — a one-year swing that Evercore ISI values at $4.8 billion in 2028 quality-bonus payments, and that HealthcareDive pegs at over $3 billion in additional revenue. The mechanics don't kick in until 2028, which is why HUM is being repriced today: bonus-eligibility is the announcement, the cash lands later.

The trough matters as much as the peak: in HUM's 2025 reporting year, benefit ratios ran 93% in Q4 and 90.2% for the full year as utilization outran pricing. The Star Ratings collapse capped the bonus revenue at the same time medical costs were spiking. Putting both back — the ratings rebuild and a 91.2% Q2 2026 insurance-segment benefit ratio, in line with management's prior guidance — is the version of the Humana story the Street hasn't had since before the 2025 MA crisis.

The Oct. 9 CMS release punished UNH, ELV, CVS and Centene on the same metric that rewarded HUM. UnitedHealthcare fell to 67% of members in 4-star+ plans (from 81%), Aetna to 69% (from 84%), Elevance's Anthem to 45% (from 53%), and Centene dropped to 9% (from 18%). Clover Health — too small to move the tape — surged to 100% (from 3%). The dispersion is why HUM is the only name in the print with an $596 broker target riding on it. The same CMS rules distribute the bonus pool; HUM won the redistribution.

Three structural reasons explain why HUM's Star-Ratings exposure is fundamentally different from UNH's and ELV's, even though the Oct. 9 read treated them as comparable managed-care stories. First, mix: Humana is roughly 83% Medicare Advantage by premium, with a thin commercial book, so almost the entire bonus-pool math lands on a single rating curve. UnitedHealth and Elevance carry large employer-commercial and Medicaid books where Star Ratings don't apply at all — their earnings are diversified, but so is their upside. Second, scale of the lift: Humana's book went from a structural 1.4 million members in 4-star+ plans (20% of seven million) to 6.65 million in a single rating cycle — an arithmetic move that an UNH book (9.3 million members) can't replicate by the same percentage point swing (it would need to add ~1.4 million 4-star members just to stay flat). Third, Humana's owned-delivery backstop — CenterWell senior primary care, CenterWell Home Health and the CenterWell Pharmacy — is the toolkit the company actually used to drive those screenings; ELV and CVS don't have an equivalent in-house MA-primary-care footprint at the same depth.

The Blue Cross Blue Shield Association published an analysis on Sep 23, 2026 (reported Sep 24) putting $942 million of incremental hospital-billing costs on AI-assisted coding tools over 2023–2025 across the Blues system — a 37% → 40% rise in complex-coded inpatient claims without a matching rise in treatment intensity. The library has, for a few weeks, grouped HUM alongside UNH and ELV as \"exposed\" to that dynamic. The actual transmission is materially weaker for Humana. The BCBSA dataset is commercial-claims driven (Blue Health Intelligence); HUM's commercial book is thin, and CMS uses its own HCC risk-adjustment model — different inputs, different audit cadence — which determines what HUM actually gets paid on the MA side. The $942M is squarely a BCBSA member-plan commercial problem; Humana is on the insurer end of the same equation only by extension, and the Star Ratings rework just gave it a separate, much larger lever (the bonus pool) that the BCBSA peers don't have.

The supply-chain pressure that defined 2025–2026 for MA — hospitals out of network, providers refusing to take plan rates — is still very much live. Centra Health in Virginia and Kettering Health in Ohio both stopped accepting Humana MA in 2026; Becker's Hospital Review counts 28 to 34 health systems that have either dropped or refused to renew MA contracts for 2026 across the industry. Against that backdrop, HUM's Oct. 2 non-renewal of roughly 600,000 2026 MA members — and a Q3 2026 earnings preview (Nov 6) expected to walk through the post-renewal mix — looks less like a defensive pullback and more like a Star-Ratings-aligned remixing of the book: keep high-margin, high-rated counties and CenterWell-anchored lives; shed the rest.

Upstream and downstream effects run in two directions. Upstream — into the providers and pharmacy channels: Humana's CenterWell pharmacy, home health and senior-primary-care platform grew roughly 32% in Q2 2026, anchoring the care-intensity metrics (preventive visits, screenings, post-discharge follow-up) that drive Star Ratings. When a Centra or Kettering refuses to take Humana MA, the offset on the rating sheet is Humana's owned-delivery layer, which the Blues carriers and CVS/Aetna do not replicate at the same scale. Downstream — into the broker channel and the 10,000-Boomer-per-day MA-eligible cohort: every plan that gets cut at renewal is an enrollment slot for either a HUM plan that scores 4+ stars or for a competing UNH/ELV product that didn't. KFF's June 2026 enrollment update had Humana at 7.0 million MA members (20% of the 35.2-million-enrollee market) after adding 1.3 million in 2026 alone — the largest single-payer lift in the industry. The post-Oct. 9 ratings re-ranking makes that growth lead more profitable per member, not less.

Short-term, the catalysts cluster in November. HUM's Q3 2026 earnings drop on Nov 6 before market open, four to six weeks into the Medicare Annual Election Period that began Oct 15. The data points that will move the stock are: how 2027 plan enrollment lands versus the 600K-non-renewal base; whether benefit-ratio commentary for FY 2026 holds the 90.1–90.5% band; what management says about broker incentive payments for the new 4-star plan footprint; and any 2027 EPS guide lift that pulls forward the bonus-payment math. Two days later, Oct 13, UNH reports Q3 (consensus $2.82, sales ~$113B per tastylive): with UnitedHealthcare's 4-star share backsliding to 67% and Optum Health operating margins under scrutiny (Conway guided a ~10% membership dip before re-expansion in 2027), the question is whether the diversified operator can keep its 2026 guide ($16.25 EPS raised to $16.85 in Q1 commentary) while its MA engine deteriorates at the rating layer.

Long-term (one to three years), the test of the HUM thesis isn't the Oct. 9 print — it's whether the ratings stick under the CMS measurement rules now being normalized. The CMS voluntary recalculation of 2026 MA Star Ratings in June 2026 (unlocking ~$428 million in additional 2027 industry-wide bonus payments per Modern Healthcare) and the CY 2027 Final Rule's restoration of 4-star bonus eligibility both expand the pool HUM is swimming in. But CMS can also tighten the methodology — the same 2027 rule cut roughly a dozen Star-Rating measures and Trade-the-Methodology risk is real, particularly on readmissions and the drug-plan (PDP) measure. The structural call: HUM now carries a forward P/E of 24.3 against UNH's 16.6 and ELV's 13.7 — the premium is the rating-driven 2028 bonus optionality, and that premium is only justified if Oct 2027 ratings confirm Oct 2027's print. Two consecutive 95% prints turn the rating rebuild into structural earnings power; one reset, and HUM is back to the 2025–2026 trading range.